Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Time to clinical worsening has been proposed as a primary end point in clinical trials of pulmonary arterial hypertension (PAH); however, neither standardized nor validated definitions of clinical worsening across PAH trials exist. This study aims to evaluate a proposed definition of clinical worsening within a large prospective, observational registry of patients with PAH with respect to its value as a predictor of proximate (within 1 year) risk for subsequent major events (ie, death, transplantation, or atrial septostomy). Methods We assessed overall 2-year survival and survival free from major events to determine the relationship between clinical worsening and major events among adults with hemodynamically defined PAH (N = 3,001). Freedom from clinical worsening was defined as freedom from worsening functional class (FC), a ≥ 15% reduction in 6-min walk distance (6MWD), all-cause hospitalization, or the introduction of parenteral prostacyclin analog therapy. Results In the 2 years of follow-up, 583 patients died. Four hundred twenty-six died after a documented clinical worsening event, including FC worsening (n = 128), a ≥ 15% reduction in 6MWD (n = 118), all-cause hospitalization (n = 370), or introduction of a prostacyclin analog (n = 91). Patients who experienced clinical worsening had significantly poorer subsequent 1-year survival postworsening than patients who did not worsen (P Conclusions Clinical worsening was highly predictive of subsequent proximate m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [287]
In the citing paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [287]
Citations
Cites
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citationPrimary Pulmonary Hypertension: A National Prospective Study
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,039
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Self-citationLong-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. É. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,383
Pulmonary Arterial Hypertension
Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. E., Barst, R. J., Benza, R. L., Liou, T. G., Turner, M., et al. (2010) · Chest · doi:10.1378/chest.09-1140 · Cited by 1,178
Self-citationMedical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Self-citationSurvival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
Humbert, M., Sitbon, O., Yaïci, A., Montani, D., O'Callaghan, D. S., Jaïs, X., Parent, F., Savale, L., Natali, D., Günther, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00057010 · Cited by 674
Analysing Survival Data From Clinical Trials and Observational Studies
(1996) · Technometrics · doi:10.1080/00401706.1996.10484530 · Cited by 663
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Predicting Survival in Patients With Pulmonary Arterial Hypertension
Benza, R. L., Gomberg-Maitland, M., Elliott, C. G., Farber, H. W., Foreman, A. J., Frost, A. E., McGoon, M. D., Pasta, D. J., Selej, M., Burger, C. D., et al. (2019) · Chest · doi:10.1016/j.chest.2019.02.004 · Cited by 643
“0 predicted clinical worsening, which is defined as subsequent all-cause hospitalization or initiation of parenteral prostacyclin therapy for any reason.(24) In contrast to the definition from Frost et al,(24) New York Heart Association/WHO functional class (FC) and 6-min walk distance (6MWD) were not included in the…”
MethodSelf-citationCombination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis
Lajoie, A. C., Lauzière, G., Lega, J.-C., Lacasse, Y., Martin, S., Simard, S., Bonnet, S., & Provencher, S. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00027-8 · Cited by 235
Clinical trial design and new therapies for pulmonary arterial hypertension
Sitbon, O., Gomberg-Maitland, M., Granton, J., Lewis, M. I., Mathai, S. C., Rainisio, M., Stockbridge, N. L., Wilkins, M. R., Zamanian, R. T., & Rubin, L. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01908-2018 · Cited by 196
Metadata
- Authors
- Frost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D.
- Affiliations
- Baylor College of Medicine (US)
- University of Colorado Denver (US)
- Allegheny General Hospital (US)
- Actelion (United States) (US)
- Mayo Clinic (US)
- Corresponding author
- Frost, Adaani E.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 144
- Issue
- 5
- Pages
- 1521-1529
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2085328300
- Semantic Scholar
- 03ce7f931507745cca05f0abadd9ff31e2c49cb4
- Cited by
- 90
- References
- 30
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 6 · 2019: 15 · 2018: 10 · 2017: 5 · 2016: 8 · 2015: 6 · 2014: 7 · 2013: 1
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer
- Biogen
- United Therapeutics Corporation
- IC Design Education Center
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- pulmonary arterial hypertension, clinical deterioration, primary endpoint, survival, mortality, functional class, 6-minute walk distance, hospitalization, lung transplantation, atrial septostomy, clinical trial endpoints
- MeSH terms
- Antihypertensive Agents, Exercise Test, Female, Follow-Up Studies, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prognosis, Prospective Studies, Epoprostenol, Registries, Time Factors, United States, Survival Rate, Disease Progression, Disease Management, Familial Primary Pulmonary Hypertension
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension. https://app.cochat.ai/papers/10.1378/chest.12-3023
- The paper
- Frost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D. (2013). Evaluation of the Predictive Value of a Clinical Worsening Definition Using 2-Year Outcomes in Patients With Pulmonary Arterial Hypertension. Chest. https://doi.org/10.1378/chest.12-3023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.